In addition, ACSL4 may be an effective therapeutic target for the regulation of multiple transporters associated with anti-cancer resistance through the mammalian target of rapamycin (mTOR) pathway, thereby restoring drug sensitivity in breast cancer with poor prognosis (Orlando et al., 2019). The gene discussed is MTOR; the disease is breast carcinoma.